Biocon’s arm acquires R&D capital assets from Pfizer Healthcare India

24 Sep 2019 Evaluate

Biocon’s subsidiary -- Biocon Biologics has acquired R&D capital assets for 60,000 sq. ft. state-of-the-art ‘bench to pilot scale’ Biologics research facility at TICEL Bio Park in Chennai, India. Biocon Biologics has acquired these assets from Pfizer Healthcare India.

The new facility provides Biocon Biologics a significant time advantage in comparison to setting up a Greenfield R&D project and will accelerate the global development of its biosimilars portfolio.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

305.20 -5.85 (-1.88%)
03-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1508.40
Dr. Reddys Lab 6332.85
Cipla 1424.40
Zydus Lifesciences 992.00
Lupin 1663.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.